Sunshine Biopharma (NASDAQ:SBFM) Releases Earnings Results

Sunshine Biopharma (NASDAQ:SBFM) announced its quarterly earnings data on Thursday. The company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.05, FiscalAI reports. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 27.69%. The company had revenue of $9.26 million for the quarter, compared to the consensus estimate of $8.70 million.

Sunshine Biopharma Price Performance

NASDAQ SBFM opened at $1.15 on Friday. The firm’s fifty day moving average price is $1.82 and its 200 day moving average price is $6.90. Sunshine Biopharma has a 12 month low of $1.10 and a 12 month high of $24.30. The company has a market capitalization of $575,000.00, a price-to-earnings ratio of -0.11 and a beta of 1.16.

Hedge Funds Weigh In On Sunshine Biopharma

Several large investors have recently bought and sold shares of SBFM. Citadel Advisors LLC grew its holdings in shares of Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after purchasing an additional 14,656 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Sunshine Biopharma in the 3rd quarter valued at about $32,000. Finally, Virtu Financial LLC acquired a new stake in shares of Sunshine Biopharma in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 41.98% of the company’s stock.

Analyst Ratings Changes

SBFM has been the topic of several recent analyst reports. Wall Street Zen raised Sunshine Biopharma to a “hold” rating in a report on Saturday. Zacks Research raised Sunshine Biopharma to a “hold” rating in a report on Wednesday, May 27th. Finally, Weiss Ratings cut Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $70.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.